European center for diabetes study
Founded in 1991 by Professor Michel Pinget, the CeeD is a translational research organization made up of doctors and researchers put together to respond to the concerns of healthcare teams and the expectations of patients through laboratory research. Given the priority by the CeeD to patient comfort, the aim is to develop new treatment systems (bioartificial pancreas, free islet grafts, oral insulin) while gaining a better understanding of the physiological activity of the islets of Langerhans. Since MailPan® was conceived and studied in the CeeD laboratory, it is quite natural that the center should be Defymed’s long-standing stockholder.
Since 1978, Statice has lent its support to start-ups, SMEs and multinationals with their innovative projects, from the feasibility study phase to serial production. As a service provider in microtechnics and biomaterials, Statice has been working and supporting Defymed since its inception. Through its participation in the design and manufacture of MailPan® and ExOlin®, Statice is extensively involved in the development and validation procedures of Defymed’s medical devices.
Boasting 25 years of experience, the Centre de Transfert de Technologie du Mans (Le Mans technology transfer center) is composed of various clusters specialized in biological and medical engineering, design engineering, materials and acoustics. Involved since the very start of MailPan®, the CTTM has contributed its expertise to Defymed. Thanks to the multi-disciplinary skills of the team members of the different clusters, an innovative solution for improving the performance of semi-permeable biocompatible membranes was developed, which is a key part of the MailPan® device.
Capital Grand Est
Capital Grand Est is a regional private equity firm managing over € 100 million through various private equity funds (Alsace Croissance and Cap Innov’Est) and venture capital companies (Alsace Amorçage and Alsace Création). Capital Grand Est acquired an equity stake in Defymed, through its seed fund Cap Innov’Est, in 2015 to facilitate the industrialization phases of MailPan® and the development of ExOlin®.
Having invested in the cleantech and medtech sectors since 1999, Emertec manages nearly € 800 million. Its mission is to create value by transforming breakthrough technological innovations into commercial and financial success stories. By guaranteeing the Lorraine Materials Fund and the European Materials Fund in 2015, Emertec has demonstrated its willingness to invest in start-ups working on innovative materials. The stake in Defymed acquired by Emertec in 2013 is a sure sign of its confidence in Defymed’s potential to market its devices (MailPan® and ExOlin®).